Urology
Volume 68, Issue 6 , Pages 1263-1267 , December 2006

Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

  • Abraham Morgentaler

      Affiliations

    • Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Abraham Morgentaler, M.D., One Brookline Place, Suite 624, Brookline, MA 02445
    • ,
  • Ernani Luis Rhoden

      Affiliations

    • Division of Urology, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • Department of Urology, Federal Foundation of Medical Sciences of Porto Alegre, Porto Alegre, Brasil
    • E. L. Rhoden is supported by Coordenação de Aperfeiçoamento Pessoal de Nível Superior of Brazil and is an I-C Reseacher from Conselho Nacional de Pesquisa, Brasil.

Received 17 March 2006 ,Accepted 11 August 2006.

References 

  1. Morgentaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276:1904–1906
  2. Zhang PL, Bubley G, Upton M, et al. Pathological features of occult prostatic carcinoma in hypogonadal men. Prostate J. 2000;2:74–78
  3. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum testosterone a marker for high grade prostate cancer?. J Urol. 2000;163:824–827
  4. Schatzl G, Madersbacherm S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52–58
  5. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of FT in serum. J Clin Endocrinol Metab. 1999;84:3666–3672
  6. Mohr BA, Guay AT, O’Donnell AB, et al. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol. 2005;62:64–73
  7. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a PSA level ≤4 ng per milliliter. N Engl J Med. 2004;350:2239–2246
  8. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol. 1997;20:605–608
  9. Massengill JC, Sun L, Moul JW, et al. Pretreatment TT level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670–1675
  10. Isom-Batz G, Bianco FJ, Kattan ME, et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173:1935–1937
  11. Chodak GW, Vogelzang NJ, Caplan RJ, et al. Zoladex Study Group Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA. 1991;265:618–621
  12. Raivio T, Santti H, Schatzl G, et al. Reduced circulating androgen bioreactivity in patients with prostate cancer. Prostate. 2003;55:194–198
  13. Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol. 2003;169:1312–1315
  14. Miller LR, Partin AW, Chan DW, et al. Influence of radical prostatectomy on serum hormone levels. J Urol. 1998;160:449–453
  15. Zhang PL, Rosen S, Veeramachaneni R, et al. Association between prostate cancer and serum testosterone levels. Prostate. 2002;53:179–182
  16. Schaeffer EM, Walsh PC. Re: risks of testosterone replacement. N Engl J Med. 2004;350:2004–2006

PII: S0090-4295(06)01962-5

doi: 10.1016/j.urology.2006.08.1058

Urology
Volume 68, Issue 6 , Pages 1263-1267 , December 2006

Article Tools

* Image Usage & Resolution